Jean-Jacques Bienaimé Biography and Net Worth

Jean-Jacques Bienaimé has served as a member of our Board of Directors since March 2026. He previously served as Chief Executive Officer from May 2005 to November 2023 and as Chair of the board of directors from June 2015 to November 2023 of BioMarin Pharmaceutical Inc., a biopharmaceutical company focused on severe rare genetic disorders. From November 2002 to April 2005, Mr. Bienaimé served as Chair, Chief Executive Officer and President of Genencor, a biotechnology company focused on industrial bioproducts and targeted cancer biotherapeutics. Prior to joining Genencor, Mr. Bienaimé was Chairperson, President and Chief Executive Officer of SangStat Medical Corporation, an immunology focused biotechnology company that was later acquired by Genzyme Corporation. He became President of SangStat in 1998 and Chief Executive Officer in 1999. Prior to joining SangStat, Mr. Bienaimé held various management positions from 1992 to 1998 with Rhône Poulenc Rorer Pharmaceuticals (now known as Sanofi), including Senior Vice President of Corporate Marketing and Business Development, and Vice President and General Manager of the Advanced Therapeutics and Oncology division. He was responsible for the global launch of Taxotere and the US launch of Lovenox. He previously worked for Genentech in several marketing positions and started his career at Ciba-Geigy (now Novartis). Mr. Bienaimé is also a director of the Biotechnology Innovation Organization, chairman of the board of Keros Therapeutics and director of Incyte Corporation, Immunome and Alpha-9 Oncology. Mr. Bienaimé is a graduate from Ecole Supérieure de Commerce de Paris and holds an MBA from the Wharton School at the University of Pennsylvania.